ALTSTATION.IO

Waters Corporation (WAT) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$380.84

Change

+1.05%

Market Cap

$22.68B

Avg Volume

537.1K

Company Overview

Waters Corporation, headquartered in Milford, Massachusetts, specializes in analytical workflow solutions. The company designs and manufactures high-performance liquid chromatography and mass spectrometry systems, which are critical for various applications in the healthcare sector. Their products cater to a broad range of customers, including pharmaceuticals, clinical laboratories, and academic institutions, focusing on drug discovery, environmental testing, and nutritional safety.

Waters holds a strong competitive position as a market leader in the analytical instruments space. Their edge derives from advanced technology and a reputation for reliability, allowing them to maintain significant market share. However, they’re up against tough competition from companies like Agilent Technologies and Thermo Fisher Scientific, which continuously innovate and challenge Waters’ dominance. Market dynamics such as increasing demand for precision medicine and global health initiatives present both opportunities and potential risks, driving the need for constant adaptation.

Currently, Waters is experiencing steady growth, bolstered by a strong demand for their mass spectrometry and chromatography products. The company has recently made strategic investments in expanding its product portfolio and enhancing its software solutions to better integrate with laboratory systems. This focus on innovation is vital as they aim to capture a larger share of the expanding healthcare and life sciences markets.

Key Financials

Market Cap

$22.68B

Revenue

$3.11B

EBITDA

$1.07B

Gross Margin

59.0%

Profit Margin

20.9%

Revenue Growth

8.0%

Total Cash

$459.12M

Total Debt

$1.54B

Free Cash Flow

$450.26M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

34.97

Forward P/E

26.60

Beta

1.18

52-Week High

$415.11

52-Week Low

$275.05

EPS

$10.89

50-Day Avg

$389.61

200-Day Avg

$344.51

Price/Book

9.73

Technical Analysis

Over the past 52 weeks, Waters Corporation (WAT) has exhibited a bearish trend overall, with the stock currently down 6.5% from the previous year. The chart shows significant resistance at around $400, noted in March and again in December, while support levels are evident near $350, which was tested multiple times through the middle of the year. In late January through February, a notable bearish pattern emerged, indicating potential weakness as the price approached the resistance zone again. Recently, the stock has experienced mixed momentum, fluctuating around the $380 level, suggesting indecisiveness among investors. Currently priced at $380.84, WAT is situated above the year’s low of approximately $275 but below its high of $425, which indicates that while there is some upward support, the stock remains under pressure and could struggle to regain bullish sentiment without a decisive break above the resistance.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for Waters Corporation (WAT) stock from January 31, 2026, to February 7, 2026:

1. Major Acquisition Set to Close, Reshaping Waters Corporation

Waters Corporation is poised to finalize its significant $17.5 billion acquisition of Becton Dickinson’s Biosciences and Diagnostic Solutions business on February 9, 2026. This transformative deal, the largest in Waters’ 65-year history, has received overwhelming shareholder approval (approximately 99% of votes) and all necessary regulatory clearances. The acquisition is expected to more than double Waters’ addressable market, positioning the combined entity as a diversified leader in life sciences and diagnostics.

2. Q4 2025 Earnings Report Anticipated Amidst Acquisition Close

Waters Corporation is scheduled to report its fourth-quarter 2025 earnings on Monday, February 9, 2026, before the market opens, coinciding with the expected closing of its acquisition. Analysts are forecasting earnings per share of $4.51 on revenue of $928.1 million, which would represent a year-over-year increase of 9.8% in EPS and 6.3% in revenue. The company has a history of beating consensus EPS estimates, having done so in the last four consecutive quarters.

Market Sentiment and Analyst Recommendations

Bull Case

Waters is executing the largest acquisition in its 65-year history at exactly the right time. The $17.5 billion Becton Dickinson deal closes February 9 and doubles the addressable market overnight, transforming Waters from a pure-play analytical instruments company into a diversified life sciences and diagnostics powerhouse. The company has beaten EPS estimates four quarters running, and Q4 guidance points to 9.8% EPS growth and 6.3% revenue growth despite acquisition integration noise. Analyst sentiment is genuinely bullish — 18 buy ratings with a $416.94 mean target implies 10.6% upside, and HSBC’s $460 target suggests the market hasn’t fully priced in synergy capture. At a 34.97 P/E, Waters trades at a reasonable multiple for a company targeting mid-teens EPS growth through 2030. The balance sheet supports this: $459 million in cash and manageable debt levels give the company breathing room to execute integration without financial stress. This is a classic GARP story with a transformational catalyst already approved and closing this month.

Bear Case

The stock is down 6.5% over the past year despite the acquisition narrative, which tells you something about market conviction. Waters faces significant execution risk integrating a $17.5 billion acquisition — that’s nearly 80% of its current market cap. If integration stumbles, synergy targets miss, or there are unexpected regulatory complications post-close, the stock has nowhere to hide. The technical setup is weak: clear resistance at $400 that the stock tested and failed multiple times, with a bearish pattern forming in late January through February. At $380.84, the stock is struggling for momentum and sitting below its 52-week high of $415, suggesting investors are pricing in caution around the deal. Valuation at 34.97 P/E is only justified if the company executes flawlessly on a massive integration while maintaining organic growth — a high bar. Macro uncertainty in life sciences and diagnostics end-markets could pressure organic growth rates if the economy softens, leaving less room for error on the integration side.

What to Watch

The February 9 earnings call and acquisition close announcement is the first hard test. Listen for management commentary on integration timeline, expected synergy realization rates, and any headwinds from Becton Dickinson’s business. Q1 2026 guidance will tell you whether Waters is confident in maintaining mid-single-digit organic growth while absorbing the new business. Watch for the stock’s reaction to a break above $400 resistance — if it can’t hold that level within two weeks of close, the technical weakness is real and the bull case needs reassessment. Monitor quarterly synergy realization against targets starting in Q2 2026; any miss of 10% or more on expected cost synergies would suggest integration problems. Track the combined company’s organic growth rate through mid-2026 — if it dips below 5%, the thesis that Waters can grow mid-teens EPS through 2030 becomes questionable. Finally, watch analyst estimate revisions in the weeks following the close; downgrades would signal Street skepticism about execution.

Analyst Consensus

BUY

Based on 18 analyst opinions

Low Target

$349.00

Mean Target

$416.94

High Target

$480.00

Earnings and Financial Data

Sector

Healthcare

Industry

Diagnostics & Research

Employees

7,600

Earnings & Dividends

Next Earnings

Feb 09, 2026

EPS (Trailing)

$10.89

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is WAT a good stock to buy?

Yes, analysts recommend WAT as a Buy, with a target price of $416.94. The stock’s current price of $380.84 shows potential for upside in the near term.

What is WAT’s price target?

The analyst price target for Waters Corporation is $416.94. This suggests an upside of approximately 9.5% from the current price.

Does WAT pay a dividend?

No, Waters Corporation does not pay a dividend. Investors looking for income from dividends will need to consider other options.

What is WAT’s P/E ratio?

Waters has a P/E ratio of 34.97 and a forward P/E of 26.60. This indicates that the stock is currently valued at a premium compared to the broader market, reflecting strong growth expectations.

What is WAT’s 52-week range?

WAT’s 52-week range is $275.05 to $415.11. With its current price near the upper end, there could be volatility, but the strong analyst outlook suggests a stable investment opportunity.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.